IP Library Granted Patent US 10,987,280
Granted Patent B2
US 10,987,280 · App. 16/000,327 · Granted Apr 27, 2021

Methods, compositions, and devices for supplying dietary fatty acid needs

Inventors: Alexey L. Margolin (Newton, MA); Robert Gallotto (Newton, MA); Bhami Shenoy (South Grafton, MA)
Assignee: Alcresta Therapeutics, Inc.
A61J15/0092A23D7/011A23D7/013A23D9/013A23K20/158A23K50/30A23L29/06A23L33/115A23L33/12A23L33/40A61J15/0003A61J15/0026A61K9/0029A61K31/202A61K38/465B65D1/02B65D41/02B65D81/32B65D85/72C12Y301/00A23V2002/00C12Y301/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,987,280
App. No.
16/000,327
Granted
Apr 27, 2021
Kind
B2
Abstract

Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.

Claims (21)

1. A method of providing a nutritional formula, the method comprising:

receiving at least one of milk, infant formula, or enteral formula into a syringe device, wherein the milk, infant formula, or enteral formula comprises polyunsaturated fatty acid (PUFA) triglycerides and/or PUFA esters, and wherein the syringe device comprises:

a container for receiving the milk, infant formula, or enteral formula;

at least one opening in the container; and

a lipase immobilized within the container;

exposing the milk, infant formula, or enteral formula to the immobilized lipase within the syringe device to hydrolyze the PUFA triglycerides and/or PUFA esters to form the nutritional formula; and

outputting the nutritional formula from the syringe device.

2. The method of claim 1 , wherein the lipase remains within the syringe device.

3. The method of claim 1 , wherein the lipase is immobilized to a structure within the syringe device.

4. The method of claim 1 , wherein outputting the nutritional formula includes introducing the nutritional formula into a feeding tube.

5. The method of claim 1 , further comprising delivering the nutritional formula to a subject for ingestion.

6. The method of claim 5 , wherein the at least one of milk, infant formula, or enteral formula is exposed to the lipase no more than 60 minutes prior to ingestion.

7. The method of claim 6 , wherein ingestion of the nutritional formula increases a plasma level of vitamin A and/or vitamin E in the subject.

8. A method of providing a nutritional formula, the method comprising:

drawing at least one of milk, infant formula, or enteral formula into a syringe;

hydrolyzing polyunsaturated fatty acid (PUFA) triglycerides and/or PUFA esters in the at least one of milk, infant formula, or enteral formula to form the nutritional formula by exposing the milk, infant formula, or enteral formula to immobilized lipase; and

outputting the nutritional formula from the syringe and into a feeding tube for ingestion by a subject.

9. The method of claim 8 , wherein the feeding tube is a nasogastric tube or a nasojejunal tube.

10. The method of claim 8 , wherein the lipase is immobilized to a structure in fluid communication with the syringe.

11. The method of claim 8 , wherein the lipase is immobilized to limit the amount of lipase that enters the nutritional formula.

12. The method of claim 8 , wherein the at least one of milk, infant formula, or enteral formula is exposed to the lipase no more than 60 minutes prior to ingestion.

Assignments (5)
SECURITY INTEREST Recorded Mar 12, 2024
From: ALCRESTA THERAPEUTICS, INC.
To: TWIN BROOK CAPITAL PARTNERS, LLC, AS AGENT
Reel/Frame 066742/0319 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT (PATENTS) AT REEL/FRAME: 058415/0114 Recorded Mar 12, 2024
From: SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY
To: ALCRESTA THERAPEUTICS, INC.
Reel/Frame 066799/0356 →
SECURITY INTEREST Recorded Dec 17, 2021
From: ALCRESTA THERAPEUTICS, INC.
To: SILICON VALLEY BANK
Reel/Frame 058415/0114 →
CHANGE OF NAME Recorded Aug 6, 2018
From: ALCRESTA, INC.
To: ALCRESTA THERAPEUTICS, INC.
Reel/Frame 046724/0185 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2018
From: GALLOTTO, ROBERT; SHENOY, BHAMI; MARGOLIN, ALEXEY L.
To: ALCRESTA, INC.
Reel/Frame 046492/0470 →
Continuity (7)
Continuation 15684430 · Aug 23, 2017
Continuation 15587513 · May 5, 2017
Continuation 15240596 · Aug 18, 2016
Continuation 14378856
Provisional Application 61719173 · Oct 26, 2012
Provisional Application 61600207 · Feb 17, 2012
Related Publication 20180280249A1 · Oct 4, 2018